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Identification of targets for cancer therapy requires the understanding of the in vivo roles
of proteins, which can be derived from studies using gene-targeted mice. An alternative
strategy is the administration of inhibitory monoclonal antibodies (mAbs), causing acute
disruption of the target protein function(s). This approach has the advantage of being a
model for therapeutic targeting. mAbs for use in mouse models can be obtained through
immunization of gene-deficient mice with the autologous protein. Such mAbs react with
both species-specific epitopes and epitopes conserved between species. mAbs against
proteins involved in extracellular proteolysis, including plasminogen activators urokinase
plasminogen activator (uPA), tissue-type plasminogen activator (tPA), their inhibitor PAI-1,
the uPA receptor (uPAR), two matrix metalloproteinases (MMP9 and MMP14), as well as
the collagen internalization receptor uPARAP, have been developed. The inhibitory mAbs
against uPA and uPAR block plasminogen activation and thereby hepatic fibrinolysis in vivo.
Wound healing, another plasmin-dependent process, is delayed by an inhibitory mAb
against uPA in the adult mouse. Thromboembolism can be inhibited by anti-PAI-1 mAbs
in vivo. In conclusion, function-blocking mAbs are well-suited for targeted therapy in mouse
models of different diseases, including cancer.
Keywords: mouse monoclonal antibodies, extracellular proteolysis, collagen internalization, in vivo models,
plasminogen activation
INTRODUCTION
Most of our understanding of the in vivo roles of extracellu-
lar proteases, their cellular receptors and inhibitors is derived
from studies using gene-targeted mice. The phenotype of a gene-
deficient mouse can, however, be influenced by redundancy, when
the function of the protein encoded for by the inactivated gene
is compensated due to overlapping functions between proteins
(Page-McCaw et al., 2007; Stevens et al., 2012). Identification of
the in vivo function of a protease/receptor in an adult mouse can be
obtained by administration of inhibitory monoclonal antibodies
(mAbs), causing acute disruption of the target protein function(s),
further offering the advantage of directly serving as a model for
therapeutic targeting. In order to avoid immunogenicity effects in
mice, the mAbs used should be of murine origin. Development of
such mAbs requires immunization of gene-deficient mice with the
autologous target protein.
Generation of mAbs against murine proteases using gene-
deficient mice was first described by Declerck et al. (1995a). Mice
lacking the gene encoding either of the two main plasminogen acti-
vators, i.e., tissue-type plasminogen activator (tPA) and urokinase
plasminogen activator (uPA), were immunized with murine tPA
(mtPA) and muPA, respectively. Sera from the immunized mice
had high titers of anti-mtPA and anti-muPA antibodies, while
similar immunizations of wild-type mice resulted in no or little
reactivity toward mtPA and muPA, consistent with these proteins
being self-antigens in wild-type mice (Opdenakker et al., 2003).
In this review, the properties of mouse mAbs, all generated
by use of gene-deficient mice, will be described with respect to
specificity, epitope location, cross-reactivity with the homologous
protein from other species (conserved epitopes), and inhibitory
function in vitro and in vivo. The antibody-mediated in vivo effect
will be compared with that observed in gene-deficient mice to
reveal similarities or changes between acute disruption of function
in the adult animal and genetic disruption in utero.
MONOCLONAL ANTIBODIES AGAINST MURINE
PLASMINOGEN ACTIVATORS
To generate mAbs against mtPA, mice were immunized twice
and subsequently boosted with 10µg recombinant mtPA before
spleen cell isolation and fusion to myeloma cells. Hybridomas were
selected for their ability to secrete antibodies reacting with mtPA
using ELISA, resulting in the isolation of 203 hybridomas from two
fusions. The amount of coating antigen in the ELISA was rather
high (200 ng mtPA/well), allowing antibodies with relatively low
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affinity to be isolated. Of the 203 mAbs, 21 were selective for mouse
tPA, while the residual mAbs cross-reacted with tPA from one or
more species, i.e., rat, human, and vampire-bat tPA. Importantly,
no anti-mtPA mAbs recognized muPA (Declerck et al., 1995a).
The mAbs were also assayed for their inhibitory effect on the
ability of tPA to activate plasminogen (Figure 1). Interestingly,
it was demonstrated that of the 21 mAbs recognizing epitopes
specific for mtPA, six were inhibitory, whereas 105 of the 182 cross-
reacting mAbs were inhibitory (Declerck et al., 1995a). Hence,
based on the apparent correlation between inhibitory proper-
ties and cross-reactivity, it was suggested that epitopes conserved
between species are functionally important for plasminogen acti-
vation (Declerck et al., 1995a). Two of the anti-mtPA mAbs were
used for design of a quantitative ELISA, enabling measurements of
mtPA in tissue and body fluids from mice (Declerck et al., 1995b).
Using the same overall strategy, uPA−/− mice were immunized
with muPA, resulting in 38 hybridomas producing antibodies
against muPA (Declerck et al., 1995a). Specificity test showed
negative reaction with mtPA for all of these antibodies and interest-
ingly, none of the anti-muPA mAbs cross-reacted with human uPA
(Declerck et al., 1995a). A quantitative ELISA was designed using
two of the anti-muPA mAbs (Declerck et al., 1995b). Due to the
low affinity of these anti-muPA mAbs, the sensitivity of this assay
was 10-fold lower than that of mtPA, precluding measurements of
muPA in plasma.
In a study with the aim to generate high affinity anti-muPA
mAbs with in vivo efficacy, uPA−/− mice were immunized six
times, followed by three boosting injections with recombinant pro-
muPA (Lund et al.,2008). To ensure isolation of high affinity mAbs,
the wells were coated with low amounts of antigen (2 ng pro-
muPA/well) in the hybridoma screening ELISA, resulting in identi-
fication of nine anti-muPA mAb secreting hybridomas. Especially,
two mAbs (mU1 and mU3), possessing epitopes in the uPA B-
chain, encompassing the catalytic site, were demonstrated to inter-
fere with the function of mouse uPA. Specificity test demonstrated
no cross-reactivity with mouse tPA, and interestingly neither
FIGURE 1 | Pathways of the plasminogen activation and MMP systems
targeted by mouse mAbs blocking the functions of the proteases and
receptors. Degradation of various components of the extracellular matrix
involves both plasmin-mediated breakdown and degradation by MMPs, such
as MMP9 and MMP14/MT1-MMP. This degradation of the extracellular matrix
is a prerequisite for tissue remodeling, which takes place during cancer
invasion. mAbs have been developed in order to target the functions of the
proteases and receptors, indicated by (a–h). tPA (a) and uPA (c) can activate
plasminogen to plasmin, which in turn mediates activation of pro-uPA to uPA
(b), when pro-uPA is bound to its receptor uPAR (d) at the cell surface. Both
uPA and tPA are inhibited by PAI-1 (e). MMP9 (f) and MMP14 (g) primarily
degrade collagen in the extracellular matrix. Collagen and cleaved fragments
hereof can bind to uPARAP and are subsequently internalized with the
receptor (h).
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antibody recognized human uPA. Both mU1 and mU3 are high
affinity antibodies. mU3 displays higher affinity for both pro-
muPA (K D= 0.03 nM) and muPA (K D= 0.2 nM), as compared
to mU1 [pro-muPA (K D= 0.2 nM) and muPA (K D= 1.3 nM)].
These antibodies efficiently and dose-dependently block uPA-
mediated plasminogen activation. mU1 prevents both plasmin-
mediated pro-uPA activation and uPA-mediated plasminogen
activation (Figure 1), while mU3 only inhibits the latter of these
reactions.
To test the effect of these mAbs in vitro in a multicomponent
system, a cellular assay using uPA-activatable anthrax pro-toxin
(Liu et al., 2001) was employed. In this assay, a cytotoxic effect
is released as a result of cell-bound uPA activity, which serves to
cleave an engineered protective antigen, PrAg-U2. Pre-incubation
of murine monocyte macrophage-like P388D.1 cells with either
mU1 or mU3 led to significant rescue of cells simultaneously
exposed to PrAg-U2 and the recombinant toxin FP59 (Lund et al.,
2008). Interestingly, the rescue effect of mU1 was stronger than
that of mU3 in vitro. As uPA−/− mice are insensitive to anthrax
pro-toxin treatment (Liu et al., 2003), this system was used to
determine the in vivo efficacy of mU1 and mU3 in wild-type mice.
Two injections of the mAbs (60 mg/kg/dose) were administered to
the mice prior to anthrax pro-toxin treatment. Of the wild-type
mice treated with mU1, eight out of 10 mice survived, whereas only
few mice treated with either mU3 or the isotype-matched nega-
tive control mAb survived, demonstrating mU1, but not mU3, to
possess in vivo efficacy by blocking uPA activity (Figure 2; Lund
et al., 2008, 2011a).
MONOCLONAL ANTIBODIES AGAINST muPAR
The main function of the uPA receptor (uPAR), is to localize
the proteolytic activity to the cell surface (Ellis and Danø, 1991).
uPAR also interacts with vitronectin and various integrins, thereby
possessing several biological functions independent of its role
in uPA-mediated proteolysis (Høyer-Hansen and Lund, 2007;
Smith and Marshall, 2010). Despite the multifunctional proper-
ties, uPAR−/− mice show no overt phenotype (Bugge et al., 1995).
To develop mAbs against muPAR, uPAR−/−mice were immunized
with recombinant soluble muPAR (Pass et al., 2007). The proce-
dures to generate hybridomas were identical to those described
for the muPA mAbs (Pass et al., 2007; Lund et al., 2008). One
fusion resulted in 12 hybridomas, secreting antibodies reacting
with muPAR, including six that cross-reacted with human uPAR
in Western blotting.
uPAR consist of three domains and the integrity of this struc-
ture is a prerequisite for the high affinity binding of uPA and of
vitronectin (Behrendt et al., 1996; Høyer-Hansen et al., 1997). The
epitopes of the anti-muPAR mAbs mR1 and mR3 are located on
the N-terminal muPAR domain I, while those of mR2 and mR4
are situated on muPAR domains II-III (Pass et al., 2007; Rasch
et al., 2008). They are all high affinity mAbs, with mR3 having the
highest affinity (K D= 0.5 nM). mR1, mR2, and mR4 cross-react
with human uPAR and have similar affinities for uPAR from the
two species (Rasch et al., 2008). mR1, mR2, and mR4 were all capa-
ble of blocking binding of the murine amino-terminal fragment
of muPA (mATF) to muPAR (Figure 1; Pass et al., 2007; Rasch
et al., 2008). mR1 and mR4 showed a dose-dependent inhibition of
FIGURE 2 | mU1-induced rescue of adult mice treated with a
uPA-activatable anthrax pro-toxin. (A) FVB/n wild-type mice received
intraperitoneal injections of 60 mg/kg mU1 (dotted and broken lines) or an
equivalent volume of saline (solid line; day −1 and 0), followed by injections
with the uPA-activatable anthrax pro-toxin (i.e., 0.6 mg/kg PrAg-U2+
0.4 mg/kg FP59; broken and solid lines) or saline alone (dotted line; day 0).
Survival of the mice, presented in percentage, was recorded for 7 days. (B)
FVB/n wild-type mice were treated with 60 mg/kg mU3 (dotted and broken
lines) or an equivalent volume of saline (solid line), and subsequently by
0.6 mg/kg PrAg-U2+ 0.4 mg/kg FP59 (broken and solid lines) or saline
alone (dotted line), as described in A (Lund et al., 2008).
mATF binding with IC50 values of 0.67 and 0.34 nM, respectively,
being similar to that of the biological ligand (IC50= 0.14 nM).
Intriguingly, mR3 did not interfere with the uPA-uPAR interac-
tion, even though the complete epitope of mR1 (Gårdsvoll et al.,
2011) is close to or overlapping with that of mR3, as these mAbs
are unable to bind simultaneously to muPAR (Rasch et al., 2008).
The binding site for vitronectin on uPAR is different from that
for uPA (Wei et al., 1994). Some mAbs with epitopes in domain I
of human uPAR block the binding of vitronectin (Høyer-Hansen
et al., 1997), while none of the so far characterized mAbs, reacting
with mouse uPAR domain I, prevents this interaction (Rasch et al.,
2008).
The anti-muPAR mAbs were tested in rescue experiments using
the above-described uPA-activatable anthrax pro-toxin assay (Pass
et al., 2007). The experiments were performed both in vitro and
in vivo in mice. Pre-incubation of uPAR-positive P388D.1 cells
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with mR1 resulted in significant cell rescue. For the same sys-
tem in vivo, it was previously demonstrated that uPAR−/− mice
are insensitive to treatment with the toxins, providing evidence
for the stringent need for receptor-bound uPA to release the
anthrax cytotoxic effect (Liu et al., 2003). Administration of the
anthrax pro-toxin simultaneously with two injections of mR1
(60 mg/kg/dose) to the wild-type mice, resulted in rescue of all
eight mice. Only two of seven mice treated with saline or the
negative control mAb survived, thus demonstrating in vivo effi-
cacy of mR1 by blocking the uPA-uPAR binding (Pass et al.,
2007).
MONOCLONAL ANTIBODIES AGAINST mPAI-1
PAI-1 is the primary endogenous inhibitor of both tPA and uPA.
The first reported murine mAbs against mPAI-1 were generated
using the same protocol as for the anti-mtPA mAbs (see above),
except that the immunized mice were PAI-1−/− and mPAI-1
was the antigen (Carmeliet et al., 1993; Declerck et al., 1995b).
Two fusions resulted in 64 anti-mPAI-1 mAb-producing hybrido-
mas and two mAbs were successfully employed for design of a
quantitative immunoassay for measurement of mPAI-1 in murine
plasma.
In a recent study, the aim was to generate inhibitory anti-
mPAI-1 mAbs reacting with the glycosylated form of mPAI-1
bound to vitronectin (Van De Craen et al., 2011). PAI-1 is secreted
in an active but conformationally unstable form, which rapidly
loses activity unless bound to vitronectin (Declerck et al., 1988).
The desired anti-PAI-1 mAbs should therefore also inhibit PAI-
1 activity of the PAI-1-vitronectin complex. Such anti-mPAI-1
mAbs were developed as previously described (Declerck et al.,
1995b), though with an increase in antigen dose from 10 to
55µg/injection. One fusion yielded 21 hybridomas producing
anti-mPAI-1 antibodies. Two mAbs were specific for mPAI-1,
19 cross-reacted with rat PAI-1, and 14 of these also recognized
human PAI-1. Five of the anti-mPAI-1 mAbs, reacting with epi-
topes conserved between the three species, were found to neutral-
ize PAI-1 activity, even in the presence of a 33-fold molar excess
of mouse vitronectin. In this neutralization assay, the inhibitory
effect of the mAbs was determined as the ability of mPAI-1 to
inhibit mtPA activity in the absence and presence of the anti-
bodies (Figure 1) (Declerck et al., 1995b; Van De Craen et al.,
2011).
The in vivo efficacy of the five most inhibitory mAbs was tested
in a thromboplastin-dependent mouse thromboembolism model,
designed to demonstrate the potential function of the mAbs to res-
cue injected mtPA from mPAI-1-mediated inactivation. Mice were
injected with 10 mg/kg of the mAb via the tail vein. Thromboplas-
tin was injected simultaneously with mtPA to evoke thromboem-
bolism. A reduced physical activity was used as the read-out for the
thromboembolic condition. Evaluation 15 min. after treatment,
demonstrated all five inhibitory anti-mPAI-1 mAbs to possess
in vivo efficacy, as the mAb-treated mice were more active than
control mice (Van De Craen et al., 2011). Two of these anti-mPAI-
1 mAbs have furthermore been demonstrated to decrease the level
of active mPAI-1 in mouse plasma, collected from mice treated
with lipopolysaccharide to induce high mPAI-1 levels in the blood
(Van De Craen et al., 2012).
MONOCLONAL ANTIBODIES AGAINST mMMPs
mMMP9
Matrix metalloproteinase 9 (MMP9) belongs to the subfamily of
gelatinases and is active in degradation of various components
in the extracellular matrix, including early collagen cleavage frag-
ments. Anti-mMMP9 mAbs have been generated by immuniza-
tion of MMP9−/− mice with recombinant mMMP9 (Descamps
et al., 2002; Opdenakker et al., 2003; Kolaczkowska et al., 2008).
Hybridomas were identified by ELISA, in which the wells were
coated with goat-anti-mouse IgG. Addition of hybridoma super-
natants, followed by biotinylated mMMP9 was used to identify
anti-mMMP9 producing clones. Of the 250 hybridomas secreting
anti-mMMP9 antibodies, the 16 with the strongest reactions were
selected (Kolaczkowska et al., 2008). Four of these mAbs were spe-
cific for the pro-form of mMMP9, two were specific for the active
form, and the 10 remaining reacted with pro-mMMP9 as well as
one or more of three degradation products (Kolaczkowska et al.,
2008). The mAbs reacting exclusively with the active form were
found to have MMP9 neutralizing activity (Figure 1), as measured
using a fluorogenic substrate (Opdenakker et al., 2003).
mMMP14/mMT1-MMP
All of the above-mentioned gene-deficient mice have very mild,
if at all comprised phenotypes and a normal life span (Carmeliet
et al., 1993, 1994, 1995; Bugge et al., 1995; Vu et al., 1998). The
MMP14−/− mice have in contrast a severe phenotype and a short
life span (7–13 weeks) as they develop craniofacial dysmorphism,
arthritis, osteopenia, dwarfism, and fibrosis of soft tissues due
to inadequate collagen turn-over (Holmbeck et al., 1999). To
enable generation of anti-mMMP14 mAbs, immunizations were
therefore initiated 4 weeks after birth of the MMP14−/− mice,
as compared with the usual age of 8–9 weeks. The mice were only
immunized twice, followed by three boosting injections with 15µg
recombinant soluble mMMP14 (Ingvarsen et al., 2008). Due to the
small size of their spleens, splenocytes isolated from five immu-
nized MMP14−/− mice were pooled for one fusion. Screening for
hybridomas was performed using ELISA with each well coated
with 12 ng mMMP14. Six hybridomas secreting anti-mMMP14
antibodies were isolated. The epitopes are located in the hemo-
pexin domain and/or in the membrane-proximal linker region
of mMMP14. The mAbs cross-react with the human form of
MMP14. Interestingly, one mAb is capable of stimulating the
MMP14 dimerization step on the cell surface, which is neces-
sary for MMP14-mediated activation of the soluble gelatinase,
MMP2. None of the mAbs possess any inhibitory effect on the
collagenolytic activity of mMMP14 (Figure 1; Ingvarsen et al.,
2008).
MONOCLONAL ANTIBODIES AGAINST uPARAP/ENDO180
uPARAP (also designated Endo180), a member of the mannose
receptor family, is a collagen internalization receptor and a type 1
transmembrane protein (Behrendt, 2004; Engelholm et al., 2009).
For the generation of mAbs, uPARAP−/− mice were immunized
with recombinant soluble human uPARAP (Sulek et al., 2007).
All procedures were identical to those described for generation of
mAbs against muPA and muPAR (Pass et al., 2007; Lund et al.,
2008). Interestingly, seven out of eight mAbs cross-react with
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mouse uPARAP. The anti-uPARAP mAb 5f4 was demonstrated
to inhibit cellular collagen internalization in fibroblasts (Figure 1;
Madsen et al., 2011). Due to this mechanism of action, addition
of 5f4 to wild-type cultured fibroblasts leads to accumulation of
collagen degradation products in the cell culture medium, being
similar to the collagen fragments that occur in the medium of
uPARAP−/− mouse fibroblasts, cultured without antibody addi-
tion (Jürgensen et al., 2011; Madsen et al., 2011). Although the
epitope of 5f4 is located to the N-terminal domains 1–3 of uPARAP
(Madsen et al., 2012), the antibody does not prevent binding of
uPARAP to collagen in a purified system. The capacity of blocking
collagen internalization may be related to another interesting char-
acteristic as the antibody down-regulates uPARAP expression on
the cell surface (Madsen et al., 2011).
COMPARISON OF EFFECTS OF ACUTE DISRUPTION OF
PROTEIN FUNCTION IN THE ADULT ANIMAL AND GENETIC
DISRUPTION IN UTERO
Studies with gene-deficient animals have demonstrated uPA to
play an important role in skin wound healing and extravascular
fibrin clearance in the liver as well as the presence of a strong
redundancy between uPA and tPA (Bugge et al., 1996). Mice defi-
cient in uPA or tPA have a marginal delay in wound healing, while
uPA−/−;tPA−/− double-deficient mice display a significant delay
compared to wild-type littermates (Lund et al., 2006). To study
the effect of acute disruption of uPA function in wound healing,
tPA−/− mice were treated with mU1 (60 mg/kg), administered
according to the mAb half-life (Jögi et al., 2010). Importantly, mU1
caused a delay in wound healing, resulting in a healing time, which
was not significantly different from that of the uPA−/−;tPA−/−
mice (Jögi et al., 2010). Consistent with uPA and tPA being the
main plasminogen activators, a reduced level of plasmin was
detected in wound extracts from mU1-treated tPA−/− mice, and
the plasmin level was similar to that in uPA−/−;tPA−/− mice.
This underscores that administration of mU1 blocks plasminogen
activation in vivo (Jögi et al., 2010).
Both uPA−/−;tPA−/− and uPAR−/−;tPA−/− mice sponta-
neously develop hepatic fibrin deposits (Bugge et al., 1996). While
uPA−/− mice occasionally display fibrin accumulation in the liver,
no deposits have been detected in neither tPA−/− nor uPAR−/−
mice (Bugge et al., 1996). Hence, to evaluate the effect of mU1 and
mR1 on in vivo fibrin clearance, tPA−/− mice were treated with
either mAb (Jögi et al., 2007; Lund et al., 2008). Systemic treatment
with mU1 as well as with mR1 resulted in hepatic fibrin accumula-
tion in tPA−/− mice, being indistinguishable from the depositions
observed in corresponding double-deficient mice (Jögi et al., 2007;
Lund et al., 2008).
A recent study has demonstrated uPARAP−/− mice to possess
increased accumulation of both total fibrillar collagen and colla-
gen type IV upon CCl4-induced liver fibrosis (Madsen et al., 2012).
Hepatic collagen deposition in wild-type mice with liver fibrosis
thus seems as a suitable model for testing the in vivo efficacy of the
anti-uPARAP mAbs.
In addition to the overlapping roles between uPA and tPA
in certain physiological processes, it was recently demonstrated
that ablation of MMP9 in combination with either plasminogen
activator impairs normal gestation, resulting in a non-Mendelian
distribution of the off-spring (Lund et al., 2011b). Furthermore,
combined deficiency in MMP9 and uPA, but not tPA, causes a sig-
nificant delay in wound healing as compared to the single-deficient
and wild-type littermate control mice. Notably, a compensatory
upregulation of uPA activity is seen in wound extracts from MMP9
deficient mice (Lund et al., 2011b). Consequently, these sys-
tems are interesting for studies using the described mAbs against
mouse uPA and MMP9, employing wild-type or the relevant
single-deficient mice for treatment.
CONCLUSION
Monoclonal antibodies (mAbs) raised in gene-deficient mice have
the unique ability to recognize epitopes conserved between species.
Additional reactivity with species-specific epitopes provides a
more diverse reactivity with the antigen than mAbs raised in
wild-type mice. Furthermore, some studies have suggested cross-
reacting mAbs to be superior inhibitors to mAbs only reacting with
species-specific epitopes. Compared to small molecular inhibitors,
the mAbs possess an amazing selectivity, have a long half-life in
circulation (3–6 days; Pass et al., 2007; Lund et al., 2008), and are
therefore well-suited for therapy experiments in mouse models of
different diseases, including cancer.
ACKNOWLEDGMENTS
We thank all the partners in Microenvimet for fruitful and
inspiring discussions and collaborations. We thank John Post
for graphic assistance. Much of the research leading to these
results has received funding from the European Community’s Sev-
enth Framework Program FP7/2007–2011 under grant agreement
n˚201279.
REFERENCES
Behrendt, N. (2004). The uroki-
nase receptor (uPAR) and
the uPAR-associated protein
(uPARAP/Endo180): mem-
brane proteins engaged in
matrix turnover during tissue
remodeling. Biol. Chem. 385,
103–136.
Behrendt, N., Rønne, E., and Danø,
K. (1996). Domain interplay in the
urokinase receptor. Requirement for
the third domain in high affinity
ligand binding and demonstration
of ligand contact sites in distinct
receptor domains. J. Biol. Chem. 271,
22885–22894.
Bugge, T. H., Flick, M. J., Danton, M. J.,
Daugherty, C. C., Rømer, J., Danø,
K., Carmeliet, P., Collen, D., and
Degen, J. L. (1996). Urokinase-type
plasminogen activator is effective in
fibrin clearance in the absence of its
receptor or tissue-type plasminogen
activator. Proc. Natl. Acad. Sci. U.S.A
93, 5899–5904.
Bugge, T. H., Suh, T. T., Flick, M. J.,
Daugherty, C. C., Rømer, J., Sol-
berg, H., Ellis, V., Danø, K., and
Degen, J. L. (1995). The receptor for
urokinase-type plasminogen activa-
tor is not essential for mouse devel-
opment or fertility. J. Biol. Chem.
270, 16886–16894.
Carmeliet, P., Bouche, A., De, C. C.,
Janssen, S., Pollefeyt, S., Wyns, S.,
Mulligan, R. C., and Collen, D.
(1995). Biological effects of disrup-
tion of the tissue-type plasminogen
activator, urokinase-type plasmino-
gen activator, and plasminogen acti-
vator inhibitor-1 genes in mice. Ann.
N. Y. Acad. Sci. 748, 367–381.
Carmeliet, P., Kieckens, L., Schoonjans,
L., Ream, B., van, N. A., Prendergast,
G., Cole, M., Bronson, R., Collen,
D., and Mulligan, R. C. (1993).
Plasminogen activator inhibitor-1
gene-deficient mice. I. Generation
by homologous recombination and
characterization. J. Clin. Invest. 92,
2746–2755.
Carmeliet, P., Schoonjans, L., Kieck-
ens, L., Ream, B., Degen, J., Bron-
son, R., De, V. R., van den Oord, J.
J., Collen, D., and Mulligan, R. C.
(1994). Physiological consequences
of loss of plasminogen activator
gene function in mice. Nature 368,
419–424.
www.frontiersin.org June 2012 | Volume 3 | Article 122 | 5
Lund et al. Monoclonal antibodies against mouse proteins
Declerck, P. J., Carmeliet, P., Verstreken,
M., De, C. F., and Collen, D. (1995a).
Generation of monoclonal antibod-
ies against autologous proteins in
gene-inactivated mice. J. Biol. Chem.
270, 8397–8400.
Declerck, P. J., Verstreken, M., and
Collen, D. (1995b). Immunoassay
of murine t-PA, u-PA and PAI-1
using monoclonal antibodies raised
in gene-inactivated mice. Thromb.
Haemost. 74, 1305–1309.
Declerck, P. J., De, M. M., Alessi, M.
C., Baudner, S., Paques, E. P., Preiss-
ner, K. T., Müller-Berghaus, G., and
Collen, D. (1988). Purification and
characterization of a plasminogen
activator inhibitor 1 binding pro-
tein from human plasma. Identifi-
cation as a multimeric form of S
protein (vitronectin). J. Biol. Chem.
263, 15454–15461.
Descamps, F. J., Martens, E., and Opde-
nakker, G. (2002). Analysis of gelati-
nases in complex biological fluids
and tissue extracts. Lab. Invest. 82,
1607–1608.
Ellis,V., and Danø, K. (1991). Plasmino-
gen activation by receptor-bound
urokinase. Semin. Thromb. Hemost.
17, 194–200.
Engelholm, L. H., Ingvarsen, S., Jür-
gensen, H. J., Hillig, T., Madsen, D.
H., Nielsen, B. S., and Behrendt,
N. (2009). The collagen receptor
uPARAP/Endo180. Front. Biosci. 14,
2103–2114.
Gårdsvoll, H., Jacobsen, B., Krieg-
baum, M. C., Behrendt, N., Engel-
holm, L., Østergaard, S., and Ploug,
M. (2011). Conformational regula-
tion of urokinase receptor function:
impact of receptor occupancy and
epitope-mapped monoclonal anti-
bodies on lamellipodia induction. J.
Biol. Chem. 286, 33544–33556.
Holmbeck, K., Bianco, P., Caterina, J.,
Yamada, S., Kromer, M., Kuznetsov,
S. A., Mankani, M., Robey, P. G.,
Poole, A. R., Pidoux, I., Ward, J.
M., and Birkedal-Hansen, H. (1999).
MT1-MMP-deficient mice develop
dwarfism, osteopenia, arthritis, and
connective tissue disease due to
inadequate collagen turnover. Cell
99, 81–92.
Høyer-Hansen, G., Behrendt, N., Ploug,
M., Danø, K., and Preissner, K. T.
(1997). The intact urokinase recep-
tor is required for efficient vit-
ronectin binding: receptor cleavage
prevents ligand interaction. FEBS
Lett. 420, 79–85.
Høyer-Hansen, G., and Lund, I. K.
(2007). Urokinase receptor variants
in tissue and body fluids. Adv. Clin.
Chem. 44, 65–102.
Ingvarsen, S., Madsen, D. H., Hillig, T.,
Lund, L. R., Holmbeck, K., Behrendt,
N., and Engelholm, L. H. (2008).
Dimerization of endogenous MT1-
MMP is a regulatory step in the
activation of the 72-kDa gelati-
nase MMP-2 on fibroblasts and
fibrosarcoma cells. Biol. Chem. 389,
943–953.
Jögi, A., Pass, J., Høyer-Hansen, G.,
Lund, L. R., Nielsen, B. S., Danø,




hepatic fibrin deposition in tissue-
type plasminogen activator deficient
mice. J. Thromb. Haemost. 5,
1936–1944.
Jögi, A., Rønø, B., Lund, I. K.,
Nielsen, B. S., Ploug, M., Høyer-
Hansen, G., Rømer, J., and Lund,
L. R. (2010). Neutralisation of
uPA with a monoclonal antibody
reduces plasmin formation and
delays skin wound healing in tPA-
deficient mice. PLoS. One. 5, e12746.
doi:10.1371/journal.pone.0012746
Jürgensen, H. J., Madsen, D. H.,
Ingvarsen, S., Melander, M. C.,
Gårdsvoll, H., Patthy, L., Engel-
holm, L. H., and Behrendt, N.
(2011). A novel functional role of
collagen glycosylation: interaction
with the endocytic collagen recep-
tor uparap/ENDO180. J. Biol. Chem.
286, 32736–32748.
Kolaczkowska, E., Arnold, B., and
Opdenakker, G. (2008). Gelati-
nase B/MMP-9 as an inflammatory
marker enzyme in mouse zymosan
peritonitis: comparison of phase-
specific and cell-specific produc-
tion by mast cells, macrophages and
neutrophils. Immunobiology 213,
109–124.
Liu, S., Aaronson, H., Mitola, D. J.,
Leppla, S. H., and Bugge, T. H.
(2003). Potent antitumor activity
of a urokinase-activated engineered
anthrax toxin. Proc. Natl. Acad. Sci.
U.S.A 100, 657–662.
Liu, S., Bugge, T. H., and Leppla, S. H.
(2001). Targeting of tumor cells by
cell surface urokinase plasminogen
activator-dependent anthrax toxin.
J. Biol. Chem. 276, 17976–17984.
Lund, I. K., Illemann, M., Thurison,
T., Christensen, I. J., and Høyer-
Hansen, G. (2011a). uPAR as anti-
cancer target: evaluation of bio-
marker potential, histological local-
ization, and antibody-based therapy.
Curr. Drug Targets 12, 1744–1760.
Lund, I. K., Nielsen, B. S., Almholt,
K., Rønø, B., Hald, A., Illemann,
M., Green, K. A., Christensen, I. J.,
Rømer, J., and Lund, L. R. (2011b).
Concomitant lack of MMP9 and
uPA disturbs physiological tissue
remodeling. Dev. Biol. 358, 56–67.
Lund, I. K., Jögi, A., Rønø, B., Rasch,
M. G., Lund, L. R., Almholt, K.,
Gårdsvoll, H., Behrendt, N., Rømer,
J., and Høyer-Hansen, G. (2008).
Antibody-mediated targeting of the
uPA proteolytic function neutralizes
fibrinolysis in vivo. J. Biol. Chem.
283, 32506–32515.
Lund, L. R., Green, K. A., Stoop, A.
A., Ploug, M., Almholt, K., Lilla,
J., Nielsen, B. S., Christensen, I. J.,
Craik, C. S., Werb, Z., Danø, K.,
and Rømer, J. (2006). Plasmino-
gen activation independent of uPA
and tPA maintains wound healing
in gene-deficient mice. EMBO J. 25,
2686–2697.
Madsen, D. H., Ingvarsen, S., Jürgensen,
H. J., Melander, M. C., Kjøller, L.,
Moyer, A., Honore, C., Madsen, C.
A., Garred, P., Burgdorf, S., Bugge,
T. H., Behrendt, N., and Engelholm,
L. H. (2011). The non-phagocytic
route of collagen uptake: a distinct
degradation pathway. J. Biol. Chem.
286, 26996–27010.
Madsen, D. H., Jürgensen, H. J., Ing-
varsen, S., Melander, M. C., Vainer,
B., Egerod, K. L., Hald, A., Rønø,
B., Madsen, C. A., Bugge, T. H.,
Engelholm, L. H., and Behrendt, N.
(2012). Endocytic collagen degrada-
tion: a novel mechanism involved in
the protection against liver fibrosis.
J. Pathol. 227, 94–105.
Opdenakker, G., Van Den Steen, P.
E., Laureys, G., Hunninck, K., and
Arnold, B. (2003). Neutralizing
antibodies in gene-defective hosts.
Trends Immunol. 24, 94–100.
Page-McCaw, A., Ewald, A. J., and
Werb, Z. (2007). Matrix metallopro-
teinases and the regulation of tissue
remodelling. Nat. Rev. Mol. Cell Biol.
8, 221–233.
Pass, J., Jögi, A., Lund, I. K., Rønø, B.,
Rasch, M. G., Gårdsvoll, H., Lund, L.
R.,Ploug,M.,Rømer,J.,Danø,K.,and
Høyer-Hansen, G. (2007). Murine
monoclonal antibodies against
murine uPA receptor produced in
gene-deficient mice: inhibitory
effects on receptor-mediated uPA
activity in vitro and in vivo. Thromb.
Haemost. 97,1013–1022.
Rasch, M. G., Pass, J., Illemann, M.,
Høyer-Hansen, G., and Lund, I. K.
(2008). Discrimination of different
forms of the murine urokinase plas-
minogen activator receptor on the
cell surface using monoclonal anti-
bodies. J. Immunol. Methods 339,
55–65.
Smith, H. W., and Marshall, C. J.
(2010). Regulation of cell signalling
by uPAR. Nat. Rev. Mol. Cell Biol. 11,
23–36.
Stevens, L. J., and Page-McCaw, A.
(2012). A secreted MMP is required
for reepithelialization during
wound healing. Mol. Biol. Cell 23,
1068–1079.
Sulek, J., Wagenaar-Miller, R. A., Shire-
man, J., Molinolo, A., Madsen, D.
H., Engelholm, L. H., Behrendt, N.,
and Bugge, T. H. (2007). Increased
expression of the collagen internal-
ization receptor uPARAP/Endo180
in the stroma of head and neck
cancer. J. Histochem. Cytochem. 55,
347–353.
Van De Craen, B., Scroyen, I.,Abdelnabi,
R., Brouwers, E., Lijnen, H. R.,
Declerck, P. J., and Gils, A. (2011).
Characterization of a panel of mon-
oclonal antibodies toward mouse
PAI-1 that exert a significant profib-
rinolytic effect in vivo. Thromb. Res.
128, 68–76.
Van De Craen, B., Scroyen, I., Vranckx,
C., Compernolle, G., Lijnen, H. R.,
Declerck, P. J., and Gils, A. (2012).
Maximal PAI-1 inhibition in vivo
requires neutralizing antibodies
that recognize and inhibit glyco-
sylated PAI-1. Thromb. Res. 129,
e126–e133.
Vu, T. H., Shipley, J. M., Bergers, G.,
Berger, J. E., Helms, J. A., Hana-
han, D., Shapiro, S. D., Senior, R.
M., and Werb, Z. (1998). MMP-
9/gelatinase B is a key regulator of
growth plate angiogenesis and apop-
tosis of hypertrophic chondrocytes.
Cell 93, 411–422.
Wei, Y., Waltz, D. A., Rao, N., Drum-
mond, R. J., Rosenberg, S., and
Chapman, H. A. (1994). Identifica-
tion of the urokinase receptor as an
adhesion receptor for vitronectin. J.
Biol. Chem. 269, 32380–32388.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 03 April 2012; accepted: 07 June
2012; published online: 28 June 2012.
Citation: Lund IK, Rasch MG, Ing-
varsen S, Pass J, Madsen DH, Engelholm
LH, Behrendt N and Høyer-Hansen G
(2012) Inhibitory monoclonal antibodies
against mouse proteases raised in gene-
deficient mice block proteolytic functions
in vivo. Front. Pharmacol. 3:122. doi:
10.3389/fphar.2012.00122
This article was submitted to Frontiers in
Pharmacology of Anti-Cancer Drugs, a
specialty of Frontiers in Pharmacology.
Copyright © 2012 Lund, Rasch, Ing-
varsen, Pass, Madsen, Engelholm,
Behrendt and Høyer-Hansen. This is
an open-access article distributed under
the terms of the Creative Commons
Attribution Non Commercial License,
which permits non-commercial use,
distribution, and reproduction in other
forums, provided the original authors
and source are credited.
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs June 2012 | Volume 3 | Article 122 | 6
